Understanding how well African women need to take PrEP to prevent HIV
PrEP adherence-concentration thresholds associated with HIV protection among African women
This study is looking at how well a medication called PrEP can help prevent HIV in African women, especially during pregnancy, and it wants to find out how consistently women need to take it to get the best protection.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10773059 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV among African women, particularly during pregnancy. It aims to clarify the necessary levels of adherence to PrEP that are required for optimal protection against HIV. By analyzing pharmacologic data and adherence patterns, the study seeks to establish clear thresholds for PrEP use that can be applied in real-world settings. The research will involve collecting data from women in Africa to better understand how PrEP works in their specific context.
Who could benefit from this research
Good fit: Ideal candidates for this research are African women, particularly those who are at risk of HIV infection and may be considering or currently using PrEP.
Not a fit: Patients who are not at risk of HIV or those who do not identify as women may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved guidelines for PrEP use among African women, enhancing their protection against HIV.
How similar studies have performed: Previous studies have shown success in understanding PrEP adherence in men, but this research aims to fill a gap in knowledge specific to women, making it a novel approach.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Mugwanya, Kenneth Kiggundu — University of Washington
- Study coordinator: Mugwanya, Kenneth Kiggundu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.